LTX-315 (Synonyms: K-K-W-W-K-K-W-Dip-K-NH2, Ruxotemitide, Oncopore) is a synthetic anticancer peptide derived from human lactoferrin, has the potential to adopt an amphipathic helical coil structure and was designed for intralesional treatment of tumors. LTX-315 was highly active against both murine and human melanoma cell lines in vitro, while displaying low EC50 cytotoxic activity against human red blood cells. Furthermore, when syngeneic B16 melanomas were treated intralesionally, a majority of the animals (~80%) treated with LTX-315 experienced a complete and long-lasting tumor regression. LTX-315 (Ruxotemitide, Oncopore) kills cancer cells through Bax/Bak-regulated mitochondrial membrane permeabilization.
Camilio KA, Rekdal O, Sveinbju00f6rnsson B. LTX-315 (Oncoporeu2122): A short synthetic anticancer peptide and novel immunotherapeutic agent. Oncoimmunology. 2014